Communiqués Vertex Pharmaceuticals Incorporated Sao Paulo

Actions

VRTX34

BRVRTXBDR001

Produits pharmaceutiques

Temps Différé Sao Paulo 18:21:25 18/08/2026			Varia. 5j.	Varia. 1 janv.
86,64 ^BRL	-85,05%		+1,69%	+10,74%

12/08	Vertex dispose de multiples catalyseurs au sein de son portefeuille avec un profil risque-rendement favorable, selon RBC	MT
11/08	Vertex Pharmaceuticals Incorporated : Daiwa Securities réitère son opinion positive sur le titre	ZM

Communiqués

05/08	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending JUNE 30, 2026 (Form 10-Q)	PU
03/08	Vertex: Q2 Earnings Snapshot	AQ
03/08	Vertex Reports Second Quarter 2026 Financial Results	BU
07/07	Vertex to Announce Second Quarter 2026 Financial Results on August 3rd	BU
07/07	Vertex Signs Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance for ALYFTREK for the Treatment of Cystic Fibrosis	AQ
06/07	Vertex to Acquire Crinetics Pharmaceuticals	BU
02/07	Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia	BU
11/06	Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions	BU
05/06	Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference	BU
03/06	Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10	BU
01/06	Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy	BU
11/05	Vertex to Participate in Upcoming May Investor Conferences	BU
07/05	Vertex Announces CASGEVY Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	AQ
06/05	Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany	BU
06/05	Vertex Pharmaceuticals Incorporated : Quarterly Report for Quarter Ending MARCH 31, 2026 (Form 10-Q)	PU
04/05	Vertex Pharmaceuticals Incorporated : Q1 26 VRTX Earnings Presentation	PU
04/05	Vertex: Q1 Earnings Snapshot	AQ
04/05	Vertex Reports First Quarter 2026 Financial Results	BU
16/04	Vertex Pharmaceuticals Incorporated : 2025 Corporate Responsibility Report	PU
16/04	Vertex Pharmaceuticals Incorporated : 2025 Data Summary	PU
06/04	Vertex to Announce First Quarter 2026 Financial Results on May 4th	BU
01/04	Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States	BU
25/03	Vertex Pharmaceuticals Incorporated : 2025 (2025 Political Engagement Principles)	PU
13/03	AM Best Affirms Credit Ratings of Torreyana Insurance Company, Inc	AQ
09/03	Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy	BU